~~UNITED~~U.S. ~~STATES~~ SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of ~~report~~Report (date of earliest event reported): ~~November~~March ~~19,~~8 ~~2012~~2013

~~SAFECODE~~SafeCode ~~DRUG~~Drug ~~TECHNOLOGIES~~Technologies ~~CORP.~~Corp

(Exact ~~Name~~name of ~~Registrant~~registrant as ~~Specified~~specified in its ~~Charter~~charter)

~~Commission File No.: 333-174167~~Delaware

Delaware	99-0362484
(State of Incorporation)	(I.R.S. Employer Identification No.)
6 Meever HaMiltah Street, Jerusalem, Israel	97761
(Address of Principal Executive Offices)	(ZIP Code)

(State or other jurisdiction of incorporation)

~~Registrant's~~99-0362482 ~~Telephone~~(Commission ~~Number,~~File ~~including area~~No.) ~~code:~~(IRS ~~+972-50~~Employer ~~783~~Identification ~~9976~~No.)

~~Check~~c/o ~~the~~Joel ~~appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):~~Klopfer

~~¨ Written communications~~6 ~~pursuant~~Meever toHamiltah Rule 425 under the Securities Act (17 CFR 230.425) ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))Street

~~Item~~Jerusalem ~~1.01~~97761, ~~Entry Into a Material Definitive Agreement.~~Israel

~~On November 15, 2012, Safecode Drug Technologies Corp.~~ (~~the~~Address ~~"Registrant"~~and ~~or "Safecode"), entered into a license agreement (the "License Agreement")~~telephone ~~with~~number ~~Medisafe 1 Technologies Corp., a Delaware corporation and a public reporting company engaged in the development~~ of ~~medical technology~~principal ~~products~~executive ~~("Medisafe").~~offices ~~Pursuant to the License Agreement, Safecode, as licensee, has been granted a non - exclusive license to manufacture, market~~ and ~~otherwise~~place commercially exploit world-wide Medisafe's patented device for administering medicine in correct dosages to the correct patient . The License Agreement provides that as consideration for the license, Safecode will issue to Medisafe ten million shares of its common stock valued at $.70 per share. The License Agreement provides for certain adjustments in the event that Safecode's shares are not equal to or greater than that price twelve months after the effective date. The License Agreement is attached hereto as Exhibit 99.1.business)

~~Item~~(former ~~9.01~~name ~~Financial~~or ~~Statements~~former ~~and~~address, ~~Exhibits~~if changed since last report)

~~(b)~~Check ~~The~~the ~~following~~appropriate ~~documents~~box ~~are~~below ~~filed~~if by the ~~Registrant as exhibits to this current report on~~ Form 8-K orfiling ~~incorporated~~is byintended to ~~reference~~simultaneously ~~herein.~~satisfy ~~Any~~the ~~document~~filing ~~incorporated~~obligation byof ~~reference~~the isregistrant ~~identified~~under ~~by a~~any ~~parenthetical~~of ~~reference to~~ the ~~SEC~~following ~~filing~~provisions ~~that~~(see ~~included~~General ~~such document~~Instruction A.2. below)

Exhibit No.		Description
99.1		License Agreement between the Registrant and Medisafe 1 Technologies Corp. dated November 15, 2012, filed herewith.

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

~~SIGNATURES~~¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14-12)

~~Pursuant to the requirements of the Securities Exchange Act~~¨ of Pre-commencement ~~1934,~~communications ~~the~~pursuant ~~Registrant has duly caused this report~~ to beRule ~~signed~~14d-2(b) onunder ~~its behalf by~~ the ~~undersigned~~Exchange ~~hereunto~~Act ~~duly~~(17 ~~authorized~~CFR 240.14d-2(b))

~~Safecode~~¨ Pre-commencement ~~Drug~~communications ~~Technologies~~pursuant ~~Corp.~~to ~~By:~~Rule ~~/s/~~13ed-4(c) ~~Joel~~under ~~Klopfer~~the ~~Name:~~Exchange ~~Joel~~Act ~~Klopfer~~(17 ~~Title:~~CFR ~~President Date: November 19, 2012~~240.13e-4(c))

Item 3.02 Unregistered Sales of Equity Securities

On March 8 2013 the Registrant issued a total of 20,000,000 shares of additional common stock of the Issuer, to Itamar Zer CFO and Secretary of the Issuer . The shares of common stock were issued as 2013 compensation.

The shares were issued without registration under Section 5 of the Securities Act of 1933 in reliance on the exemption from registration contained in Section 4(2) of the Securities Act.

Section 5 -- Corporate Governance and Management

Item 5.03 Amendments to Articles of Incorporation or Bylaws, Change in Fiscal Year.

On or about April 1 2012 , the Company received written consents in lieu of a meeting of stockholders from holders of a majority of the shares of Common Stock representing in excess of 50.1 % of the total issued and outstanding shares of voting stock of the Company approving a Certificate of Amendment to the Certificate of Incorporation of the Company, pursuant to which the Company will change , increase the authorized capital of the Company to a total of 1,000,000,000 shares of common stock with a par value of $0.0001 per share.

The Company however only or about March 5 2013 , filed with the Secretary of the State of Delaware to increase the authorized capital of the Corporation to be 1,000,000,000 shares of common stock, par value of $0.0001.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934 the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: March 11 2013

	Medisafe 1 Technologies Corp.

	By:	Joel Klopfer
		Joel Klopfer
		Title: President and Director (Principal Executive Officer)

Filing Compare · SAFECODE DRUG TECHNOLOGIES CORP.